ECSP10010156A - Piperidino-dihidrotienopirimidinas sustituidas - Google Patents

Piperidino-dihidrotienopirimidinas sustituidas

Info

Publication number
ECSP10010156A
ECSP10010156A EC2010010156A ECSP10010156A ECSP10010156A EC SP10010156 A ECSP10010156 A EC SP10010156A EC 2010010156 A EC2010010156 A EC 2010010156A EC SP10010156 A ECSP10010156 A EC SP10010156A EC SP10010156 A ECSP10010156 A EC SP10010156A
Authority
EC
Ecuador
Prior art keywords
diseases
piperidino
dihidrotienopirimidinas
replaced
well
Prior art date
Application number
EC2010010156A
Other languages
English (en)
Inventor
Pascale Pouzet
Christoph Hoenke
Ralf Anderskewitz
Horst Dollinger
Rolf Goeggel
Peter Nickolaus
Domnic Martyres
Klaus Klinder
Dennis Fiegen
Thomas Fox
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010156A publication Critical patent/ECSP10010156A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a nuevas piperidino-dihidrotienopirimidinas de la fórmula 1, así como a sales farmacológicamente compatibles de las mismas, 1,en donde X es SO o SO2, pero de preferencia es SO, y en donde R1, R2, R3 y R4 pueden tener los significados mencionados en la reivindicación 1, así como composiciones farmacéuticas que contienen a estos compuestos. Estas nuevas piperidino-dihidrotienopirimidinas son apropiadas para el tratamiento de trastornos o enfermedades de las vías respiratorias o gastrointestinales, enfermedades inflamatorias de las articulaciones, la piel o los ojos, enfermedades del sistema nervioso periférico o central o enfermedades cancerígenas.
EC2010010156A 2007-10-19 2010-05-05 Piperidino-dihidrotienopirimidinas sustituidas ECSP10010156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118901 2007-10-19

Publications (1)

Publication Number Publication Date
ECSP10010156A true ECSP10010156A (es) 2010-06-29

Family

ID=39154006

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010156A ECSP10010156A (es) 2007-10-19 2010-05-05 Piperidino-dihidrotienopirimidinas sustituidas

Country Status (33)

Country Link
US (1) US8754073B2 (es)
EP (3) EP2380891B1 (es)
JP (2) JP5150728B2 (es)
KR (1) KR101548975B1 (es)
CN (2) CN101827852B (es)
AR (1) AR069075A1 (es)
AT (1) ATE542825T1 (es)
AU (1) AU2008313660B2 (es)
BR (1) BRPI0818006B8 (es)
CA (1) CA2705414C (es)
CL (1) CL2008003096A1 (es)
CY (2) CY1112703T1 (es)
DK (2) DK2610258T3 (es)
EA (1) EA019480B1 (es)
EC (1) ECSP10010156A (es)
ES (2) ES2381452T3 (es)
HR (2) HRP20120334T1 (es)
MA (1) MA31845B1 (es)
ME (1) ME01330B (es)
MX (1) MX2010004026A (es)
MY (1) MY153979A (es)
NZ (1) NZ585346A (es)
PE (2) PE20091386A1 (es)
PL (2) PL2215092T3 (es)
PT (2) PT2215092E (es)
RS (1) RS52271B (es)
SI (2) SI2610258T1 (es)
TN (1) TN2010000175A1 (es)
TW (1) TWI421077B (es)
UA (1) UA99309C2 (es)
UY (1) UY31405A1 (es)
WO (1) WO2009050248A1 (es)
ZA (1) ZA201001683B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
JP5538231B2 (ja) * 2007-10-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロチエノ［３，２−ｄ］ピリミジンおよびその中で使用される中間体の調製
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
SI2610258T1 (sl) * 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
EP2215093B1 (de) 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
JP2012519160A (ja) * 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬
EP2555773A1 (de) 2010-04-08 2013-02-13 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2011124525A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
JP6307525B2 (ja) * 2013-02-04 2018-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の置換縮合ピリミジン化合物
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN104892720B (zh) * 2014-03-07 2016-10-26 华东师范大学 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
EP3480198B1 (en) * 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
US11365204B2 (en) 2017-09-20 2022-06-21 UNION therapeutics A/S Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
LT3700529T (lt) 2017-10-23 2025-10-10 Naujas veikliųjų medžiagų derinys, skirtas progresuojančių fibrozinių intersticinių plaučių ligų (pf-ild) gydymui
WO2019115775A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115774A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115776A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
WO2020048827A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
CA3234847A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
PL4426298T3 (pl) 2021-12-09 2026-07-20 Boehringer Ingelheim International Gmbh Nowe kombinacje terapeutyczne zawierające pirfenidon i inhibitor pde4 do leczenia postępujących włókniejących śródmiąższowych chorób płuc
CN119343352A (zh) * 2022-06-02 2025-01-21 西藏海思科制药有限公司 Pde4b抑制剂及其用途
TW202408518A (zh) * 2022-06-16 2024-03-01 大陸商武漢人福創新藥物研發中心有限公司 Pde4b抑制劑
CN115040503B (zh) * 2022-07-26 2023-10-10 云南民族大学 螺环二烯酮型木脂素类化合物在制药中的应用
JP2025528779A (ja) * 2022-08-09 2025-09-02 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｐｄｅ４ｂ阻害剤及びその用途
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
EP4596554A4 (en) 2022-09-29 2025-12-10 Suzhou Arkbiopharmaceutical Co Ltd Fused AZA Cyclic Compound, its Preparation Process and its Use in Medicine
CN118871444A (zh) * 2023-02-28 2024-10-29 上海翊石医药科技有限公司 二氢噻吩并嘧啶衍生物的制备方法和用途
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
EP4678644A1 (en) 2023-04-13 2026-01-14 Shanghai Yidi Biotechnology Co., Ltd. Substituted dihydrothienopyrimidine compound, preparation method therefor, and use thereof
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
EP4761728A2 (en) * 2023-08-17 2026-06-24 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
CN120398908A (zh) * 2024-02-01 2025-08-01 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE663693A (es) 1965-03-31
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
JP2003520042A (ja) 2000-01-24 2003-07-02 アイシス・ファーマシューティカルス・インコーポレーテッド 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
AU2002214996B2 (en) 2000-10-12 2007-03-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
CN101100472A (zh) 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
CA2450961C (en) 2001-06-22 2010-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
EP1654385A4 (en) 2003-05-16 2006-11-08 Wisconsin Alumni Res Found PROCESS FOR THE INSULATION AND CLONING OF HIGH-MOLECULAR POLYNUCLEOTIDE MOLECULES FROM THE ENVIRONMENT
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
MX338455B (es) * 2003-10-02 2016-04-18 Dsm Ip Assets Bv Produccion de altos niveles de dha en microalgas usando cantidades modificadas de cloruro y potasio.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
WO2005061483A2 (en) 2003-12-23 2005-07-07 Bio-Medisinsk Innovasjon As Modulators of peripheral 5-ht receptors
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
JP2008540486A (ja) 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
EP1847543A1 (de) * 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
HRP20090395T1 (hr) 2006-04-19 2009-08-31 Boehringer Ingelheim International Gmbh Dihidrotienpirimidini za liječenje upalnih bolesti
PT2137196E (pt) 2007-04-20 2010-12-16 Glaxo Group Ltd Compostos tricíclicos contendo azoto como agentes antibacterianos
JP5538231B2 (ja) * 2007-10-18 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロチエノ［３，２−ｄ］ピリミジンおよびその中で使用される中間体の調製
WO2009052288A1 (en) * 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
CA2702447A1 (en) * 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh New phenyl-substituted piperazino-dihydrothienopyrimidines
SI2610258T1 (sl) * 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
BRPI0818448A2 (pt) 2007-10-19 2015-05-12 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
EP2215093B1 (de) 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
FR2922550B1 (fr) * 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
WO2010097332A1 (de) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
JP2012519160A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する組み合わせ薬
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
CY1112703T1 (el) 2016-02-10
AR069075A1 (es) 2009-12-30
EA201000609A1 (ru) 2010-10-29
MX2010004026A (es) 2010-04-30
RS52271B (sr) 2012-10-31
EP2610258B1 (de) 2014-08-27
MA31845B1 (fr) 2010-11-01
JP5150728B2 (ja) 2013-02-27
PL2215092T3 (pl) 2012-07-31
EP2380891B1 (de) 2013-12-11
ME01330B (me) 2013-12-20
PL2610258T3 (pl) 2015-02-27
CA2705414A1 (en) 2009-04-23
BRPI0818006B1 (pt) 2019-10-22
SI2610258T1 (sl) 2014-12-31
BRPI0818006B8 (pt) 2021-05-25
CN101827852A (zh) 2010-09-08
CY1115858T1 (el) 2017-01-25
DK2215092T3 (da) 2012-05-07
EP2610258A1 (de) 2013-07-03
CN104069112A (zh) 2014-10-01
EP2215092B1 (de) 2012-01-25
US20110021501A1 (en) 2011-01-27
UA99309C2 (ru) 2012-08-10
NZ585346A (en) 2011-09-30
PE20131463A1 (es) 2013-12-23
UY31405A1 (es) 2009-05-29
CL2008003096A1 (es) 2010-02-12
TN2010000175A1 (fr) 2011-11-11
JP2013064001A (ja) 2013-04-11
JP2011500640A (ja) 2011-01-06
EP2215092A1 (de) 2010-08-11
ES2381452T3 (es) 2012-05-28
ES2524910T3 (es) 2014-12-15
WO2009050248A1 (de) 2009-04-23
BRPI0818006A2 (pt) 2015-12-22
TW200918074A (en) 2009-05-01
HRP20141153T1 (hr) 2015-02-13
DK2610258T3 (da) 2014-11-10
TWI421077B (zh) 2014-01-01
SI2215092T1 (sl) 2012-04-30
ZA201001683B (en) 2010-10-27
KR20100100807A (ko) 2010-09-15
HK1145677A1 (en) 2011-04-29
PE20091386A1 (es) 2009-10-17
PT2215092E (pt) 2012-04-10
CA2705414C (en) 2016-05-24
US8754073B2 (en) 2014-06-17
PT2610258E (pt) 2014-10-24
AU2008313660A1 (en) 2009-04-23
JP5615889B2 (ja) 2014-10-29
HRP20120334T1 (hr) 2012-05-31
AU2008313660B2 (en) 2013-11-07
CN101827852B (zh) 2014-07-30
MY153979A (en) 2015-04-30
EP2380891A1 (de) 2011-10-26
ATE542825T1 (de) 2012-02-15
EA019480B1 (ru) 2014-04-30
KR101548975B1 (ko) 2015-09-01

Similar Documents

Publication Publication Date Title
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
UY30287A1 (es) Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY30812A1 (es) Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
DOP2009000291A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
PA8632201A1 (es) Derivados de fenol y tiofenol 3-0 4-monosustituidos utiles como ligandos de h3
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
BRPI0808353B8 (pt) usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados
BRPI0516626A (pt) pteridinas substituìdas e uso das mesmas
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
UY29640A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmacéuticos.
BR112014011108A2 (pt) derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides